Novo Nordisk reported a 65% increase in Q1 2026 operating profit, driven by a provision reversal related to the US 340B Drug Pricing Program and strong sales of its new Wegovy pill for obesity. Adjusted sales excluding the provision reversal fell 4% due to lower prices but were supported by GLP-1 volume growth. The Wegovy pill, launched in January 2026, quickly reached over 2 million prescriptions, marking the strongest GLP-1 launch in the US. Novo Nordisk raised its 2026 outlook, expecting adjusted sales and operating profit growth between -4% and -12% at constant exchange rates, reflecting confidence in GLP-1 product demand and ongoing pipeline progress.
Novo Nordisk's shares have risen about 27% due to strong commercial growth of oral Wegovy, which holds 89% of new U.S. prescriptions compared to Eli Lilly's 11%. Over 80% of these prescriptions are from new GLP-1 patients, expanding the market rather...
Citi has increased its price target for Novo Nordisk to DKK330 ahead of the company's Q2 results, citing strong sales from the Wegovy pill launch. The broker raised its 2026 sales and operating income estimates by 4-5%, and earnings per share forecas...
Novo Nordisk initiated a share repurchase program starting February 2026, aiming to buy back up to DKK 15 billion of B shares within 12 months. As of July 17, 2026, the company has repurchased approximately 24.96 million B shares at an average price ...
Fangzhou Inc. has launched Kyinsu®, the world's first once-weekly basal insulin/GLP-1 receptor agonist combination therapy, on its AI-powered Internet hospital platform in China, the first global market for this treatment. This therapy reduces insuli...
Novo Nordisk's stock has surged 40% since April, driven by the success of its oral Wegovy pill, which is expected to see significant revenue growth by Q2 2026 as it gains international approvals. This growth is notable especially as competitor Eli Li...
